Natixis Advisors LLC Has $57.56 Million Position in Becton, Dickinson and Company $BDX

Natixis Advisors LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 80.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 307,541 shares of the medical instruments supplier’s stock after buying an additional 136,858 shares during the quarter. Natixis Advisors LLC owned approximately 0.11% of Becton, Dickinson and Company worth $57,563,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Activest Wealth Management lifted its stake in shares of Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares during the period. SOA Wealth Advisors LLC. raised its holdings in Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the last quarter. Bell Investment Advisors Inc raised its holdings in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the last quarter. Accredited Wealth Management LLC lifted its position in Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 70 shares during the period. Finally, Cornerstone Planning Group LLC boosted its stake in shares of Becton, Dickinson and Company by 463.3% in the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 139 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Down 1.1%

Shares of NYSE BDX opened at $165.34 on Tuesday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The stock has a market cap of $47.08 billion, a price-to-earnings ratio of 26.97, a P/E/G ratio of 12.12 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The company’s fifty day moving average is $192.67 and its 200-day moving average is $190.94.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has authorized a stock buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is 68.52%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,416 shares of company stock worth $674,693. 0.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have commented on BDX shares. Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Citigroup cut their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Stifel Nicolaus lifted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. JPMorgan Chase & Co. dropped their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Finally, Wells Fargo & Company reduced their target price on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $195.46.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.